Back to Top
ichorbio Citations (Resources)
-
December 22, 2025
The Phosphatase Factor: PPP2R2A Insufficiency Sensitizes NSCLC to PD-L1 Blockade via cGAS-STING Activation
The Genomic Stability-Immunity Axis
In the evolving landscape of cancer immunotherapy, the transition from "cold" to "hot" tumor microenvironments (TMEs) remains a primary therapeutic objective. A seminal paper recently published in...
-
December 20, 2025
Decoding the Mineralized Microenvironment: Autonomous Paracrine Signaling and High-Fidelity Drug Response in a Nanoscale Bone-on-a-Chip
For decades, the primary challenge in bone tissue engineering has been the "growth factor paradox." Standard in-vitro models typically rely on supraphysiological concentrations of recombinant proteins, such as RANKL and M-CSF...
-
December 16, 2025
Cytokine-Controlled Vulnerability: How TNF-α and IFN-γ Shape the Therapeutic Window for CD70-Targeted Immunotherapy in AML
How lirilumab (ICH4067) and monalizumab (ICH4071) exposed an IFN-γ–driven inhibitory shield that limits NK-cell immunotherapy
The promise of CD70-targeted therapies...
-
December 10, 2025
Targeting Immune Dysfunction: A Synergistic Approach Using Anti-PD-1 Blockade and Micronutrient Supplementation in BVDV Infection
Mechanistic insights supported by ichorbio’s in vivo PD-1 antibodies
A recent study utilizing the Bovine Viral Diarrhea Virus (BVDV) model has provided crucial insights into strategies for overcoming infection-induced...
-
November 14, 2025
Harnessing Innate Immunity: F9H4, A Substrate-Specific Strategy to Unlock Fc-Enabled Therapeutics
The efficacy of therapeutic monoclonal antibodies (mAbs) in oncology often hinges on their ability to engage innate immune effector cells, primarily Natural Killer (NK) cells and macrophages, through the Fc gamma receptor IIIa (CD16a). This engagement triggers...
-
November 10, 2025
Nutritional Immunology: Omega-3 PUFAs Synergize with Anti-PD-1 Therapy to Counter Cholesterol-Driven NSCLC Immune Evasion
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer mortality, frequently characterized by poor response rates to immune checkpoint inhibitors (ICIs). A growing body of evidence implicates nutritional factors and altered...
-
August 15, 2025
Humoral Immunity's Unexpected Role in Checkpoint Immunotherapy
A recent article published in Nature (Vol. 631, 23 July 2025) reveals that antibody-mediated humoral immunity, specifically the presence of autoantibodies (AAbs), can significantly influence the effectiveness of checkpoint immunotherapy (CPI) for cancer. The study, which used a high-throughput...
-
July 28, 2025
Oncolytic Virus Expressing Non-Secreted DR-18 Cytokine Induces Potent, Systemic Antitumor Immunity
A recent study published in
Molecular Therapy: Oncology (Vol. 33, Sept 2025) demonstrates the therapeutic potential of a novel oncolytic vaccinia...
